MedTrace Logo

A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

NCT07107230 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 380

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with advanced solid tumors in Part 2.

Conditions

  • Colorectal Neoplasms

Interventions

DRUG

JNJ-95437446

JNJ-95437446 will be administered.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-15
Primary Completion
2027-11-18
Completion
2028-04-24
FDA Drug
Yes

Countries

  • United States
  • South Korea
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07107230 on ClinicalTrials.gov